What is Survodutide? A Researcher's Guide to the GLP-1/Glucagon Dual Agonist

Survodutide (BI 456906) is a synthetic dual agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It represents a distinct approach within the incretin research landscape — combining GLP-1R-mediated appetite suppression with glucagon receptor-mediated energy expenditure, without the GIP receptor component found in Tirzepatide or Retatrutide.

What is Survodutide?

Survodutide is a fatty acid-conjugated peptide engineered for once-weekly dosing. It was developed by Boehringer Ingelheim and is currently under clinical investigation for obesity and non-alcoholic steatohepatitis (NASH/MASH). Its dual GLP-1R/GCGR profile distinguishes it from GLP-1 mono-agonists and from GIP-containing dual and tri-agonists, making it a valuable tool for dissecting the specific contributions of glucagon receptor agonism to metabolic outcomes.

Its two receptor targets are:

  • GLP-1 receptor (GLP-1R) — involved in insulin secretion, appetite suppression, and gastric emptying
  • Glucagon receptor (GCGR) — involved in hepatic glucose production, energy expenditure, and lipolysis

Mechanism of Action

Survodutide’s dual receptor profile produces complementary metabolic effects:

  • GLP-1R agonism — suppresses appetite via central and peripheral mechanisms, slows gastric emptying, and stimulates glucose-dependent insulin secretion
  • GCGR agonism — increases energy expenditure through thermogenesis, promotes hepatic fat oxidation and lipolysis, and reduces hepatic lipid accumulation

The glucagon receptor component is of particular research interest for liver disease models — GCGR agonism promotes hepatic lipid clearance, making Survodutide a compound of significant interest in NASH/MASH research.

Why Survodutide is of Research Interest

Survodutide’s GLP-1R/GCGR profile without GIP receptor involvement makes it a useful tool for comparative incretin pharmacology. Key areas of ongoing research include:

  • Obesity and body weight regulation models
  • Non-alcoholic steatohepatitis (NASH/MASH) and liver fat research
  • Energy expenditure and thermogenesis studies
  • Comparative GLP-1/glucagon vs. GLP-1/GIP receptor pharmacology
  • Hepatic lipid metabolism research
  • Cardiovascular risk factor modulation

Survodutide vs. Other Incretin Compounds

Understanding Survodutide’s distinct receptor profile:

  • Semaglutide — GLP-1R mono-agonist
  • Tirzepatide — GLP-1R/GIPR dual-agonist
  • Survodutide — GLP-1R/GCGR dual-agonist (no GIP); distinct hepatic and energy expenditure profile
  • Retatrutide — GLP-1R/GIPR/GCGR tri-agonist

Sourcing Survodutide for Research

Research-grade Survodutide should be sourced from suppliers providing batch-specific Certificates of Analysis (CoA) confirming purity (>98%), identity, and potency. Lyophilised formats offer optimal stability for laboratory storage.

At Aura Peptides, our Survodutide is supplied as a research-grade lyophilised peptide with full CoA documentation, available as single vials or in 10x bulk packs for high-volume research programmes.

For research purposes only. Not intended for human or veterinary use.

Back to blog